GlucoTrack Prepares FDA Submission for Implantable CBGM Trial

GlucoTrack ( (GCTK) ) has issued an announcement.

On March 27, 2026, Glucotrack recapped a series of 2024–2025 milestones that have positioned it to submit an Investigational Device Exemption to the U.S. Food and Drug Administration in the second quarter of 2026 for a U.S. clinical trial of its fully implantable CBGM system. The company reported completing a first-in-human in-hospital study in São Paulo, Brazil between December 13, 2024 and January 31, 2025, where its intravascular sensor achieved a Mean Absolute Relative Difference of 7.7%, 99% data capture and no serious procedure- or device-related adverse events.

A follow-on feasibility trial launched in Melbourne, Australia in July 2025 produced performance similar to the Brazilian study and generated protocol and product refinements that have been incorporated into the next planned U.S. clinical trial. Glucotrack said it has secured a U.S. trial site, engaged a specialized clinical research organization, completed targeted design iterations, and is in discussions with the FDA, with the aim of starting the U.S. study in the second half of 2026 subject to regulatory clearance.

To support commercialization, the company highlighted extensive U.S. market research pointing to unmet demand for a fully implantable CBGM and outlined a dual-source manufacturing strategy with two qualified U.S. contract partners. It also emphasized a defined reimbursement pathway and a management team drawn from leading diabetes and implantable device players, moves that collectively strengthen its operational footing and potential competitive position in the large, rapidly expanding diabetes technology market.

Glucotrack further disclosed that in October and November 2025 it secured three U.S. patents covering proprietary sensor chemistry, intravascular lead design and low-power electronics for its three-year implantable CBGM platform. These patents were described as critical to bridging the gap between short-lived subcutaneous sensors and larger pacemaker-class devices, bolstering the company’s intellectual property portfolio and supporting its long-term go-to-market strategy in continuous glucose monitoring.

The most recent analyst rating on (GCTK) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on GlucoTrack stock, see the GCTK Stock Forecast page.

Spark’s Take on GCTK Stock

According to Spark, TipRanks’ AI Analyst, GCTK is a Neutral.

The score is primarily weighed down by very weak financial performance (minimal revenue, widening losses, rising cash burn, and negative equity). Technicals also detract due to a strong downtrend despite oversold readings. Corporate events provide some offset via improved IP positioning and added capital, but valuation remains constrained by ongoing losses and no dividend.

To see Spark’s full report on GCTK stock, click here.

More about GlucoTrack

Glucotrack, Inc. is a medical technology company focused on designing, developing and commercializing novel devices for people with diabetes. The Nasdaq-listed company is developing a long-term, fully implantable continuous blood glucose monitoring (CBGM) system with three-year sensor longevity, no on-body wearable component and minimal calibration, targeting the fast-growing continuous glucose monitoring market.

Glucotrack’s CBGM measures glucose directly from blood rather than interstitial fluid, aiming to reduce lag time compared with traditional continuous glucose monitors. The system remains an investigational device under U.S. law and is being advanced through a staged global clinical and regulatory development program, with an initial emphasis on major diabetes markets such as the United States.

Average Trading Volume: 339,849

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.1M

For detailed information about GCTK stock, go to TipRanks’ Stock Analysis page.